Page last updated: 2024-11-13

mk-6096

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

MK-6096: antagonist of orexin receptors 1 and 2; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25128145
CHEMBL ID2107822
SCHEMBL ID1716633
MeSH IDM0575644

Synonyms (38)

Synonym
mk 6096
mk6096
mk-6096
[(2r,5r)-5-[(5-fluoropyridin-2-yl)oxymethyl]-2-methylpiperidin-1-yl]-(5-methyl-2-pyrimidin-2-ylphenyl)methanone
filorexant
gtpl4460
CHEMBL2107822
1088991-73-4
filorexant [usan:inn]
e6btt8va5z ,
unii-e6btt8va5z
methanone, ((2r,5r)-5-(((5-fluoro-2-pyridinyl)oxy)methyl)-2-methyl-1-piperidinyl)(5-methyl-2-(2-pyrimidinyl)phenyl)-
((2r,5r)-5-(((5-fluoropyridin-2-yl)oxy)methyl)-2-methylpiperidin-1-yl)(5-methyl-2-(pyrimidin-2-yl)phenyl)methanone
bdbm104692
D10345
us8569311, e-5
filorexant (usan)
filorexant [who-dd]
filorexant [usan]
[(2r,5r)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone
filorexant [inn]
CS-4437
SCHEMBL1716633
HY-15653
DTXSID50148764
AKOS027323764
NCGC00484077-01
filorexant(mk-6096)
methanone, [(2r,5r)-5-[[(5-fluoro-2-pyridinyl)oxy]methyl]-2-methyl-1-piperidinyl][5-methyl-2-(2-pyrimidinyl)phenyl]-
DB12158
mk-6096; filorexant
mfcd28100674
EX-A2101
[(2~{r},5~{r})-5-[(5-fluoranylpyridin-2-yl)oxymethyl]-2-methyl-piperidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-phenyl)methanone
NT5 ,
Q18355303
AC-35933
AS-82282

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" MK-6096 is an orally bioavailable potent and selective reversible antagonist of OX(1)R and OX(2)R currently in clinical development for insomnia."( Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.
Breslin, MJ; Coleman, PJ; Cox, CD; Cui, D; Doran, SM; Fox, SV; Garson, SL; Gotter, AL; Harrell, CM; Reiss, DR; Renger, JJ; Schreier, JD; Stevens, J; Tannenbaum, PL; Winrow, CJ, 2012
)
1.56
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Orexin receptor type 1Homo sapiens (human)IC50 (µMol)0.01350.00600.04450.1990AID1190417; AID1279957
Orexin receptor type 1Homo sapiens (human)Ki0.00210.00030.28763.1623AID1190415; AID1237020; AID1279994; AID1582239; AID765089
Orexin receptor type 2Homo sapiens (human)IC50 (µMol)0.01400.00040.51858.1000AID1190416; AID1280008
Orexin receptor type 2Homo sapiens (human)Ki0.00030.00020.37713.7810AID1190414; AID1237021; AID1279993; AID1582240; AID765090
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)Ki0.00030.00030.26715.0700AID765090
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
neuropeptide signaling pathwayOrexin receptor type 1Homo sapiens (human)
chemical synaptic transmissionOrexin receptor type 1Homo sapiens (human)
feeding behaviorOrexin receptor type 1Homo sapiens (human)
regulation of cytosolic calcium ion concentrationOrexin receptor type 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeOrexin receptor type 1Homo sapiens (human)
cellular response to hormone stimulusOrexin receptor type 1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayOrexin receptor type 2Homo sapiens (human)
neuropeptide signaling pathwayOrexin receptor type 2Homo sapiens (human)
chemical synaptic transmissionOrexin receptor type 2Homo sapiens (human)
feeding behaviorOrexin receptor type 2Homo sapiens (human)
regulation of circadian sleep/wake cycle, wakefulnessOrexin receptor type 2Homo sapiens (human)
circadian sleep/wake cycle processOrexin receptor type 2Homo sapiens (human)
locomotionOrexin receptor type 2Homo sapiens (human)
regulation of cytosolic calcium ion concentrationOrexin receptor type 2Homo sapiens (human)
cellular response to hormone stimulusOrexin receptor type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityOrexin receptor type 1Homo sapiens (human)
protein bindingOrexin receptor type 1Homo sapiens (human)
orexin receptor activityOrexin receptor type 1Homo sapiens (human)
peptide hormone bindingOrexin receptor type 1Homo sapiens (human)
peptide bindingOrexin receptor type 1Homo sapiens (human)
protein bindingOrexin receptor type 2Homo sapiens (human)
neuropeptide receptor activityOrexin receptor type 2Homo sapiens (human)
orexin receptor activityOrexin receptor type 2Homo sapiens (human)
peptide hormone bindingOrexin receptor type 2Homo sapiens (human)
peptide bindingOrexin receptor type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneOrexin receptor type 1Homo sapiens (human)
synapseOrexin receptor type 1Homo sapiens (human)
plasma membraneOrexin receptor type 1Homo sapiens (human)
plasma membraneOrexin receptor type 2Homo sapiens (human)
synapseOrexin receptor type 2Homo sapiens (human)
plasma membraneOrexin receptor type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID1280006Oral bioavailability in dog2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
AID1280005Oral bioavailability in rat2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
AID765089Binding affinity to orexin receptor 1 (unknown origin)2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Selective orexin receptor antagonists.
AID1279994Binding affinity to OX1R (unknown origin)2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
AID1279956Effect on sleep parameter in po dosed rat by EEG analysis2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
AID765090Binding affinity to orexin receptor 2 (unknown origin)2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Selective orexin receptor antagonists.
AID1190414Antagonist activity at human OX2R by radioligand displacement assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.
AID1280007Effect on sleep parameter in po dosed dog by EEG analysis2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
AID1280001Clearance in iv dosed rat2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
AID1280000Receptor occupancy at OX2R in rat brain assessed as drug level in plasma2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
AID1190417Antagonist activity at human OX1R by FLIPR assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.
AID1190415Antagonist activity at human OX1R by radioligand displacement assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.
AID1237021Antagonist activity at orexin-2 receptor (unknown origin)2015Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15
Recent trends in orexin research--2010 to 2015.
AID1280008Antagonist activity at human OX2R expressed in CHO cell membranes assessed as inhibition of orexin-A-induced intracellular calcium release after 120 mins2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
AID1237020Antagonist activity at orexin-1 receptor (unknown origin)2015Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15
Recent trends in orexin research--2010 to 2015.
AID1582240Displacement of [3H]4-(2,6-Difluoro-4-methoxybenzyl)-2-(5,6-dimethoxypyridin-3-yl)-2H-1,2,4-benzothiadiazin-3(4H)-one 1,1-dioxide from human wild-type OX2 receptor expressed in baculovirus infected Sf21 insect cell membranes measured after 90 mins by liqu2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis.
AID1280003Clearance in iv dosed dog2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
AID1582239Displacement of [3H]4-(2,6-Difluoro-4-methoxybenzyl)-2-(5,6-dimethoxypyridin-3-yl)-2H-1,2,4-benzothiadiazin-3(4H)-one 1,1-dioxide from human wild-type OX1 receptor expressed in baculovirus infected Sf21 insect cell membranes measured after 90 mins by liqu2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis.
AID1279997Plasma protein binding in rat2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
AID1190418Selectivity ratio of Ki for human OX1R to Ki for human OX2R2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.
AID1280009Ratio of drug level in CSF to plasma in rat2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
AID1279957Antagonist activity at human OX1R expressed in CHO cell membranes assessed as inhibition of orexin-A-induced intracellular calcium release after 120 mins2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
AID1190416Antagonist activity at human OX2R by FLIPR assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.
AID1279986Plasma protein binding in human2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
AID1280002Half life in iv dosed rat2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
AID1280004Half life in iv dosed dog2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
AID1279993Binding affinity to OX2R (unknown origin)2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
AID1280010Ratio of drug level in brain to plasma in rat2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
AID1279998Plasma protein binding in dog2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346418Human OX2 receptor (Orexin receptors)2012Neuropharmacology, Feb, Volume: 62, Issue:2
Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.
AID1346381Human OX1 receptor (Orexin receptors)2012Neuropharmacology, Feb, Volume: 62, Issue:2
Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's18 (85.71)24.3611
2020's3 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.58 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index46.50 (26.88)
Search Engine Supply Index3.90 (0.95)

This Compound (24.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (19.05%)5.53%
Reviews6 (28.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (52.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]